Tumor antigens and tumor vaccines: Peptides as immunogens
Identifieur interne : 001650 ( Istex/Checkpoint ); précédent : 001649; suivant : 001651Tumor antigens and tumor vaccines: Peptides as immunogens
Auteurs : Craig L. Slingluff Jr [États-Unis]Source :
- Seminars in Surgical Oncology [ 8756-0437 ] ; 1996-11.
English descriptors
- Teeft :
- Adjuvant, Antigen, Antigen processing, Antigenic, Antigenic peptides, Autologous, Autologous cytolytic, Autologous tumor, Bruggen, Cell lung cancers, Cell responses, Clone, Costimulatory, Costimulatory molecules, Cytokine, Cytokine secretion, Cytolytic, Cytotoxic, Dendritic, Dendritic cells, Encoding, Epitope, Eynde, Gene encoding, Human cytotoxic, Human melanoma, Human melanoma antigen, Immune, Immune recognition, Immune responses, Immunol, Immunology, Immunotherapy, Kawakami, Lymphocyte, Malignant melanoma, Melanoma, Melanoma cells, Melanoma patients, Metastatic melanoma, Natl, Natl cancer inst, Node, Other tumors, Ovarian, Ovarian cancer, Peptide, Peptide epitopes, Proc natl acad, Prostate cancer, Sarcoma, Solid tumors, Surgical oncology, Tumor, Tumor antigens, Tumor cells, Tumor immunology, Tumor vaccines, Tumorinfiltrating lymphocytes, Tyrosinase, Unique antigens, Vaccine.
Abstract
Tumor antigens recognized by human cytotoxic T lymphocytes (CTL) have been identified for multiple types of solid tumors. These include both shared and unique antigens. Unique antigens are those expressed uniquely by one patient's tumor, and shared antigens are those present on tumor cells from many different patients. Many of the shared antigens are derived from tissue‐specific differentiation antigens, oncogenes, or a set of antigens expressed only in tumors or in testis. In addition to advances in understanding tumor antigens that stimulate CTL and T‐helper cell responses, there have been advances in understanding immunity in general, including the characterization of cytokines, the recognition of the dendritic cell as an optimal antigen‐presenting cell (APC), and the characterization of costimulatory molecules as critical components of antigen presentation. Together, these developments have breathed new life into tumor immunology, and they promise to lead to a new generation of peptide‐ and cell‐based tumor vaccines. © 1996 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:703FEFEDA2B71069AA61CACB6842E19B132170ADLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumor antigens and tumor vaccines: Peptides as immunogens</title><author><name sortKey="Slingluff Jr, Craig L" sort="Slingluff Jr, Craig L" uniqKey="Slingluff Jr C" first="Craig L." last="Slingluff Jr">Craig L. Slingluff Jr</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:703FEFEDA2B71069AA61CACB6842E19B132170AD</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-MBZBD4WK-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000719</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000719</idno><idno type="wicri:Area/Istex/Curation">000719</idno><idno type="wicri:Area/Istex/Checkpoint">001650</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001650</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Tumor antigens and tumor vaccines: Peptides as immunogens</title><author><name sortKey="Slingluff Jr, Craig L" sort="Slingluff Jr, Craig L" uniqKey="Slingluff Jr C" first="Craig L." last="Slingluff Jr">Craig L. Slingluff Jr</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Department of Surgery, Division of Surgical Oncology, University of Virginia Health Sciences Center, Charlottesville</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Virginie</region></placeName><wicri:cityArea>Correspondence address: Department of Surgery, Chief, Division of Surgical Oncology, University of Virginia Health Sciences Center, Charlottesville</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Seminars in Surgical Oncology</title><title level="j" type="alt">SEMINARS IN SURGICAL ONCOLOGY</title><idno type="ISSN">8756-0437</idno><idno type="eISSN">1098-2388</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="446">446</biblScope><biblScope unit="page" to="453">453</biblScope><biblScope unit="page-count">8</biblScope><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1996-11">1996-11</date></imprint><idno type="ISSN">8756-0437</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">8756-0437</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Antigen</term><term>Antigen processing</term><term>Antigenic</term><term>Antigenic peptides</term><term>Autologous</term><term>Autologous cytolytic</term><term>Autologous tumor</term><term>Bruggen</term><term>Cell lung cancers</term><term>Cell responses</term><term>Clone</term><term>Costimulatory</term><term>Costimulatory molecules</term><term>Cytokine</term><term>Cytokine secretion</term><term>Cytolytic</term><term>Cytotoxic</term><term>Dendritic</term><term>Dendritic cells</term><term>Encoding</term><term>Epitope</term><term>Eynde</term><term>Gene encoding</term><term>Human cytotoxic</term><term>Human melanoma</term><term>Human melanoma antigen</term><term>Immune</term><term>Immune recognition</term><term>Immune responses</term><term>Immunol</term><term>Immunology</term><term>Immunotherapy</term><term>Kawakami</term><term>Lymphocyte</term><term>Malignant melanoma</term><term>Melanoma</term><term>Melanoma cells</term><term>Melanoma patients</term><term>Metastatic melanoma</term><term>Natl</term><term>Natl cancer inst</term><term>Node</term><term>Other tumors</term><term>Ovarian</term><term>Ovarian cancer</term><term>Peptide</term><term>Peptide epitopes</term><term>Proc natl acad</term><term>Prostate cancer</term><term>Sarcoma</term><term>Solid tumors</term><term>Surgical oncology</term><term>Tumor</term><term>Tumor antigens</term><term>Tumor cells</term><term>Tumor immunology</term><term>Tumor vaccines</term><term>Tumorinfiltrating lymphocytes</term><term>Tyrosinase</term><term>Unique antigens</term><term>Vaccine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tumor antigens recognized by human cytotoxic T lymphocytes (CTL) have been identified for multiple types of solid tumors. These include both shared and unique antigens. Unique antigens are those expressed uniquely by one patient's tumor, and shared antigens are those present on tumor cells from many different patients. Many of the shared antigens are derived from tissue‐specific differentiation antigens, oncogenes, or a set of antigens expressed only in tumors or in testis. In addition to advances in understanding tumor antigens that stimulate CTL and T‐helper cell responses, there have been advances in understanding immunity in general, including the characterization of cytokines, the recognition of the dendritic cell as an optimal antigen‐presenting cell (APC), and the characterization of costimulatory molecules as critical components of antigen presentation. Together, these developments have breathed new life into tumor immunology, and they promise to lead to a new generation of peptide‐ and cell‐based tumor vaccines. © 1996 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Virginie</li></region></list><tree><country name="États-Unis"><region name="Virginie"><name sortKey="Slingluff Jr, Craig L" sort="Slingluff Jr, Craig L" uniqKey="Slingluff Jr C" first="Craig L." last="Slingluff Jr">Craig L. Slingluff Jr</name></region><name sortKey="Slingluff Jr, Craig L" sort="Slingluff Jr, Craig L" uniqKey="Slingluff Jr C" first="Craig L." last="Slingluff Jr">Craig L. Slingluff Jr</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001650 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001650 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:703FEFEDA2B71069AA61CACB6842E19B132170AD
|texte= Tumor antigens and tumor vaccines: Peptides as immunogens
}}
| This area was generated with Dilib version V0.6.33. |  |